Tumor stroma as targets for cancer therapy.

Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle (2013) 1.34

Histological and molecular aspects of oral squamous cell carcinoma (Review). Oncol Lett (2014) 0.96

Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J Control Release (2014) 0.92

Whole Tumor Antigen Vaccines: Where Are We? Vaccines (Basel) (2015) 0.87

Tumor talk: understanding the conversation between the tumor and its microenvironment. Cancer Cell Microenviron (2015) 0.84

Tumor gangliosides accelerate murine tumor angiogenesis. Angiogenesis (2013) 0.82

Imaging aspects of the tumor stroma with therapeutic implications. Pharmacol Ther (2013) 0.81

C-C chemokine receptor 5 on pulmonary mesenchymal cells promotes experimental metastasis via the induction of erythroid differentiation regulator 1. Mol Cancer Res (2013) 0.80

Endothelial-mesenchymal transition in normal human esophageal endothelial cells cocultured with esophageal adenocarcinoma cells: role of IL-1β and TGF-β2. Am J Physiol Cell Physiol (2014) 0.79

Fibroblast activation protein α in tumor microenvironment: recent progression and implications (review). Mol Med Rep (2015) 0.79

Hematopoietic stem cell-derived cancer-associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment. Neoplasia (2015) 0.79

Deficient expression of aldehyde dehydrogenase 1A1 is consistent with increased sensitivity of Gorlin syndrome patients to radiation carcinogenesis. Mol Carcinog (2013) 0.79

Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. Genes Cancer (2016) 0.78

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res (2015) 0.78

Colorectal cancer and basement membranes: clinicopathological correlations. Gastroenterol Res Pract (2014) 0.78

Magnetic resonance elastography (MRE) in cancer: Technique, analysis, and applications. Prog Nucl Magn Reson Spectrosc (2015) 0.77

Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis. PLoS One (2015) 0.76

Growth of MCF-7 breast cancer cells and efficacy of anti-angiogenic agents in a hydroxyethyl chitosan/glycidyl methacrylate hydrogel. Cancer Cell Int (2017) 0.75

Microenvironmental interactions and expression of molecular markers associated with epithelial-to-mesenchymal transition in colorectal carcinoma. Int J Clin Exp Pathol (2015) 0.75

NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma. Oncol Rep (2017) 0.75

Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application. EJIFCC (2014) 0.75

Human CAFs promote lymphangiogenesis in ovarian cancer via the Hh-VEGF-C signaling axis. Oncotarget (2017) 0.75

Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma. Oncotarget (2017) 0.75

Cancer associated fibroblasts: An essential role in the tumor microenvironment. Oncol Lett (2017) 0.75

Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment. F1000Res (2017) 0.75

Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02

Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07

Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20

TGFbeta in Cancer. Cell (2008) 17.44

The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet (2010) 13.13

Putting tumours in context. Nat Rev Cancer (2001) 12.37

Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 8.63

Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24

Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62

Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol (2007) 7.20

Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med (2007) 6.47

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell (2010) 6.33

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 4.56

CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res (2004) 4.53

Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet (2005) 4.33

Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature (2009) 4.21

Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20

The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci (2000) 3.91

Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet (2002) 3.89

Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res (2007) 3.86

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood (2009) 3.84

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell (2009) 3.71

Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem (2003) 3.51

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol (2009) 3.47

Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med (2010) 3.44

The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem (2007) 3.38

Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol (2001) 3.32

No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet (2008) 3.32

Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A (2010) 3.03

The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest (1995) 3.00

Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest (1993) 2.89

Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res (2004) 2.86

Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. Curr Opin Genet Dev (2009) 2.85

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol (2010) 2.75

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res (2003) 2.73

Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest (2006) 2.68

The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.64

Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev (2007) 2.58

Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest (2011) 2.54

Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol (1996) 2.50

Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ (2006) 2.47

The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol (2008) 2.46

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res (2011) 2.39

Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol (1991) 2.38

Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev (2012) 2.33

VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22

The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res (2011) 2.22

Activation of fibroblasts in cancer stroma. Exp Cell Res (2010) 2.19

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res (2008) 2.19

Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol (2007) 2.19

Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res (2007) 2.19

Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol (2007) 2.14

Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol (2003) 2.06

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol (2010) 2.04

Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03

Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99

Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol (2007) 1.94

The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des (2004) 1.93

Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells. PLoS One (2009) 1.87

A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol (2008) 1.87

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer (1999) 1.86

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res (2002) 1.82

Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A (2009) 1.81

Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol (2009) 1.81

Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res (2007) 1.80

Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology (2009) 1.74

Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res (2004) 1.74

Targeting the tumor microenvironment. Front Biosci (2007) 1.72

T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett (2003) 1.71

Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst (2006) 1.70

Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res (2008) 1.70

Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal (2010) 1.68

IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells. Cytokine (2005) 1.66

Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res (2009) 1.65

Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis (2007) 1.63

CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Res (2003) 1.57

Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol (1999) 1.56

Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (2011) 1.56

Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest (2005) 1.55

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol (2008) 1.54

Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res (2004) 1.54

Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord (2007) 1.51

Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer (2006) 1.48

The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer (2004) 1.48

The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res (2011) 1.44

Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res (2010) 1.44

Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene (2009) 1.43

The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol (2011) 1.43

CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer (2010) 1.43

Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta (2010) 1.42

Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer (2011) 1.39

Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis (2011) 1.37

Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS One (2011) 1.37

Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther (2007) 1.35

CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci U S A (2009) 1.35

Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech Ageing Dev (2005) 1.34

A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78

Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10

The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67

The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell (2002) 6.05

The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69

Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98

Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96

Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96

Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature (2003) 2.81

Structural basis of transcription activation: the CAP-alpha CTD-DNA complex. Science (2002) 2.67

The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.64

KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.55

Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34

Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34

Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med (2005) 2.30

Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res (2004) 2.24

Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01

Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol (2003) 1.99

CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. Mol Cell (2008) 1.94

Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res (2007) 1.79

Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78

Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog (2009) 1.71

ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol (2009) 1.70

Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther (2009) 1.69

Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer (2008) 1.69

Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68

Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem (2005) 1.64

Tissue macroarray: a simple and cost-effective method for high-throughput studies. Appl Immunohistochem Mol Morphol (2003) 1.61

Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst (2008) 1.61

REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle (2009) 1.60

TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res (2013) 1.56

Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol (2005) 1.56

Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (2011) 1.56

The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer (2006) 1.55

Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol (2009) 1.53

Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res (2008) 1.53

Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells. J Biol Chem (2008) 1.52

Misregulated Wnt/beta-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res (2005) 1.51

Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle (2010) 1.48

Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer (2007) 1.48

Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res (2014) 1.46

Early detection of ovarian cancer: promise and reality. Cancer Treat Res (2002) 1.45

Vulvar Langerhans cell histiocytosis: a case report and review of the literature. Gynecol Oncol (2003) 1.43

CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res (2010) 1.42

Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res (2004) 1.41

MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol (2012) 1.38

A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc Natl Acad Sci U S A (2006) 1.37

Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer. Proc Natl Acad Sci U S A (2004) 1.34

Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst (2010) 1.33

MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol (2014) 1.33

Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Structure (2006) 1.32

Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer (2006) 1.32

Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res (2010) 1.31

CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol (2011) 1.30

Benign cystic mesothelioma of the peritoneum: a clinicopathologic study of 17 cases and immunohistochemical analysis of estrogen and progesterone receptor status. Hum Pathol (2003) 1.29

Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol (2007) 1.29

HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res (2011) 1.27

Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem (2003) 1.27

Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer (2006) 1.25

Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene (2003) 1.24

Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer (2009) 1.23

OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action. J Natl Cancer Inst (2005) 1.23

WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer (2005) 1.22

Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol (2004) 1.22

Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res (2004) 1.22

Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res (2003) 1.22

CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol (2008) 1.21

Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol (2014) 1.21

Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res (2005) 1.20

The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer. Clin Cancer Res (2011) 1.19

Comprehensive assessment of heavy metal contamination in sediment of the Pearl River Estuary and adjacent shelf. Mar Pollut Bull (2012) 1.19

Molecular basis of sphingosine kinase 1 substrate recognition and catalysis. Structure (2013) 1.18

Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem (2004) 1.17

Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle (2012) 1.16

Paris saponin II of Rhizoma Paridis--a novel inducer of apoptosis in human ovarian cancer cells. Biosci Trends (2012) 1.15

The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res (2008) 1.14

Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol (2012) 1.14

Biological significance of prolactin in gynecologic cancers. Cancer Res (2009) 1.13

The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B. Hepatology (2015) 1.12

Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol (2003) 1.12

Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. Methods Enzymol (2006) 1.12

Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis (2006) 1.11

HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol (2010) 1.11

Ovarian cancer: pathology, biology, and disease models. Front Biosci (Landmark Ed) (2009) 1.11

Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med (2008) 1.09

Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol (2004) 1.08

PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol (2009) 1.08

Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer (2005) 1.08

VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer. Am J Transl Res (2013) 1.08

An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene (2004) 1.07

INT131: a selective modulator of PPAR gamma. J Mol Biol (2009) 1.06

Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature. Ann Diagn Pathol (2005) 1.05

Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol (2008) 1.05

Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res (2008) 1.05

Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells. J Biol Chem (2009) 1.04

Epithelial ovarian cancer: focus on genetics and animal models. Cell Cycle (2009) 1.04

Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res (2006) 1.04

A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2. Am J Pathol (2007) 1.03

Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol (2008) 1.02

Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC). J Transl Med (2004) 1.02